Luye Pharma Group Ltd Luye Pharma Group, Ltd. - CEEI Burgos

Recommendations

Info

Product Pipeline Code CMC Pre-Clinical IND Phase I Phase II Phase III NDA LY03001 LY03002 LY03003 LY03004 LY03005 LYBBF LYFSD LY02001 LY04008 LY01609 LY01610 LY01611 LY01612 TS0802 TS0903 TS0904 TS0963 TS0901 CNS Cardiovascular Gastroenterology and Hepatology Oncology Metabolism
Research and Development Center • Establishment in 1998 with a dedicated team of more than 300 specialists • Focusing on the research and development of new formulations formulations, natural drugs and biotechnology products • Platforms for innovative drug screening and development, new formulation research, pharmacology, p gy, drug g safety y evaluation and etc • China GLP Drug Safety Evaluation Center • FDA cGMP Microsphere Pilot Workshop • Diff Differentiated ti t d R&D orientation i t ti • A pipeline composing over 10 products with independent IP rights
Page 1 and 2: Luye Pharma Group, Group Ltd. Ltd W
Page 3 and 4: Corperate Culture � Mission: Prof
Page 5 and 6: Locations & Facilities Beijing Beid
Page 7 and 8: Overseas Market Formulation product
Page 9 and 10: Leading position in Oncology & Immu
Page 12 and 13: The Best Seller- LI PU SU � Unlik
Page 23 and 24: Liposome Technology Platform �Key
Page 25: Strategic R&D Alliance Strategicall
Page 28 and 29: International partnership • Licen

Luye Pharma Group Ltd Luye Pharma Group, Ltd. - CEEI Burgos

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?